Clinical trial
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological…
NCT00268918 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00268918 |
|---|---|
| Title | Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients |
| Official title | A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, PTK787 |
| Enrollment | 24 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2011 |
| First posted | Dec 23, 2005 |
| Last update posted | Jul 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: